# RNN 1st Gen Model Henry Schein, Inc. Medical & hospital equipment

Stock predictor AI models:
78.38% successful of 74 deals
$ 62.92 Last close price
at 02-mar-2021


Model's trade recommendations 3.90% Return for period

-14.90% Annual return

$11.82B Market Cap

β 1.04  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period 3.90%
52wk return -51.98%
52wk Range
Sortino ratio -0.29
Sharpe ratio -0.29
Norm. RMSE 1.36%
Downside risk 30.74%
Volatility 0.00%
  • BUY Analysts consensus recommendation

Henry Schein, Inc. is the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners. The company also serves dental laboratories, government and institutional health care clinics and other alternate care sites. The company offers a comprehensive selection of products and services, including value-added solutions for operating efficient practices and delivering high-quality care. Henry Schein operates through a centralized and automated distribution network, with a selection of branded products and Henry Schein private-brand products in stock.

Industry sector: Medical

Sector classification: Medical & hospital equipment

Deep Learning based analysis and prediction model for Henry Schein, Inc. (HSIC) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for HSIC model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for HSIC.

Model is being retrained on a daily basis.

Float 153M
P/E 21.31
Shares Outstanding 154M
% Held by Insiders 1.15%
% Held by Institutions 96.49%
EPS (last reported FY) $3.60
EPS (last reported Q) $0.97
EPS, estimated (last reported Q) $0.97
Total revenues $12 B
Net income $0 B